Abstract: PO1889
Modifications of Renal Function in Cancer Patients Undergoing Repeated and Frequent Administrations of Iodinated Contrast Medium (CM): A Multicentric Retrospective Study from Italy
Session Information
- Cancer and Kidney Diseases: Nephrotoxins, RCC, and More
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Onco-Nephrology
- 1500 Onco-Nephrology
Authors
- Cosmai, Laura, Aziende Socio Sanitarie Territoriale Fatebenefratelli Sacco, Milano, Lombardia, Italy
- Pirovano, Marta, Universita degli Studi di Milano Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Milano, Lombardia, Italy
- Re Sartò, Giulia Vanessa, Universita degli Studi di Milano Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Milano, Lombardia, Italy
- Porta, Camillo, Universita degli Studi di Bari Aldo Moro, Bari, Puglia, Italy
- Gallieni, Maurizio, Aziende Socio Sanitarie Territoriale Fatebenefratelli Sacco, Milano, Lombardia, Italy
Background
Contrast-enhanced computed tomography (CECT) is the imaging of choice for the diagnosis, staging, and follow-up of cancer patients, not to take into account its role to evaluate response to oncological treatments; in fact, it has been estimated that 47% of all CECTs are prescribed by Oncologists. Comorbidities, nephrotoxic concomitant medications, as well as chronic dehydration from different causes (nausea and vomiting, diarrhea, etc …) expose cancer patients to a higher risk of developing acute kidney injury (AKI) from CM. Risk factors, definition (PC-AKI vs CI-AKI) and preventive measures have been recently reconsidered, ultimately downsizing the incidence of this adverse event.
Methods
Aim of this study was to retrospectively assess the effects on renal function of repeated CM administrations in 407 oncological patients on active treatment, collected from 5 Italian oncology departments; patients should have undergone at least 3 CECT (on the average 3.5) within a single year (Fig I).
Results
According to our study, neither significant differences in eGFR values (calculated with the CKD-EPI formula) between the baseline and the different post-CECT timepoints, nor AKI cases (defined according to the RIFLE criteria), were recorded.
Conclusion
Repeated CM administrations in cancer patients did not lead to a worsening of renal function, confirming that CI-AKI has a significantly lower incidence than previously thought. Notably, 80% of the patients examined were found to be at low-risk, highlighting some kind of reluctance of Medical Oncologists and Radiologists to perform CECTs in these patients. On the contrary, the administration of CM could, and should, be freely used, in cancer patients, even in those at a higher risk.